

PLURISTEM THERAPEUTICS INC

Form 10-Q

February 11, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2009

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _____ to _____

Commission file number 001-31392

PLURISTEM THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation or
organization)

98-0351734
(IRS Employer Identification No.)

MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905
(Address of principal executive offices)

+972-74-710-7171
(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such files).

Yes No

Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Non-accelerated filer

(Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date:
18,505,899 common shares issued as of January 20, 2010.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2009
(unaudited)

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2009

U.S. DOLLARS IN THOUSANDS

(Unaudited)

INDEX

	Page
<u>Consolidated Balance Sheets</u>	F-2-F-3
<u>Consolidated Statements of Operations</u>	F-4
<u>Statements of Changes in Stockholders' Equity (Deficiency)</u>	F-5-F-15
<u>Consolidated Statements of Cash Flows</u>	F-16-F-18
<u>Notes to Consolidated Financial Statements</u>	F-19-F-34

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

U.S. Dollars in Thousands

	December 31, 2009	June 30, 2009
	Unaudited	Audited
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$1,383	\$2,339
Short term deposit	2,500	-
Prepaid expenses	72	100
Accounts receivable from the Office of the Chief Scientist	21	383
Other accounts receivable	81	113
Total current assets	4,057	2,935
LONG-TERM ASSETS:		
Long-term deposits and restricted deposits	178	171
Severance pay fund	241	154
Property and equipment, net	1,253	1,203
Total long-term assets	1,672	1,528
Total assets	\$5,729	\$4,463

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS
U.S. Dollars in Thousands

	December 31, 2009	June 30, 2009
	Unaudited	Audited
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Trade payables	\$596	\$487
Accrued expenses	83	81
Other accounts payable	378	272
Total current liabilities	1,057	840
LONG-TERM LIABILITIES		
Long-term obligation	-	23
Accrued severance pay	288	206
	288	229
STOCKHOLDERS' EQUITY		
Share capital:		
Common stock \$0.00001 par value:		
Authorized: 100,000,000 shares as of December 31, 2009, 30,000,000 shares as of June 30, 2009.		
Issued: 18,505,899 shares as of December 31, 2009, 14,738,693 shares as of June 30, 2009.		
Outstanding: 17,913,971 shares as of December 31, 2009, 13,676,886 shares as of June 30, 2009.		
Additional paid-in capital	-(*) 40,484	-(*) 36,046
Accumulated deficit during the development stage	(36,100)	(32,652)
	4,384	3,394
	\$5,729	\$4,463

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)

U.S. Dollars in thousands (except share and per share data)

	Six months ended December 31,		Three months ended December 31,		Period from May 11, 2001 (Inception) through December 31,
	2009	2008	2009	2008	2009
Research and development expenses	\$ 2,803	\$ 2,631	\$ 1,447	\$ 1,368	\$ 19,960
Less participation by the Office of the Chief Scientist	(989)	(1,329)	(500)	(1,329)	(4,239)
Research and development expenses, net	1,814	1,302	947	39	15,721
General and administrative expenses	1,645	1,707	875	774	19,018
Know how write-off	-	-	-	-	2,474
Operating loss	(3,459)	(3,009)	(1,822)	(813)	(37,213)
Financial expenses (income), net	(11)	66	9	20	(1,113)
Net loss for the period	\$ (3,448)	\$ (3,075)	\$ (1,831)	\$ (833)	\$ (36,100)
Loss per share:					
Basic and diluted net loss per share	\$ (0.22)	\$ (0.35)	\$ (0.10)	\$ (0.09)	
Weighted average number of shares used in computing basic and diluted net loss per share	15,984,227	8,693,210	17,449,256	9,697,119	

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share data)

	Common Stock		Additional	Receipts	Deficit	Total
	Shares	Amount	Paid-in	on	Accumulated	Stockholders'
			Capital	Account	During the	Equity
				of	Development	(Deficiency)
				Common	Stage	
				Stock		
Issuance of common stock on July 9, 2001	175,500	\$ (*))	\$ 3	\$ -	\$ -	\$ 3
Balance as of June 30, 2001	175,500	(*)	3	-	-	3
Net loss	-	-	-	-	(78)	(78)
Balance as of June 30, 2002	175,500	(*)	3	-	(78)	(75)
Issuance of common stock on October 14, 2002, net of issuance expenses of \$17	70,665	(*)	83	-	-	83
Forgiveness of debt	-	-	12	-	-	12
Stock cancelled on March 19, 2003	(136,500)	(*)	(*)	-	-	-
Receipts on account of stock and warrants, net of finders and legal fees of \$56	-	-	-	933	-	933
Net loss	-	-	-	-	(463)	(463)
Balance as of June 30, 2003	109,665	\$ (*))	\$ 98	\$ 933	\$ (541)	\$ 490

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 5

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Receipts	Deficit	Total
	Shares	Amount	Paid-in	on	Accumulated	Stockholders'
			Capital	Account	During the	Equity
				of	Development	(Deficiency)
				Common	Stage	
				Stock		
Balance as of July 1, 2003	109,665	\$ (*))	\$ 98	\$ 933	\$ (541)	\$ 490
Issuance of common stock on July 16, 2003, net of issuance expenses of \$70	3,628	(*)	1,236	(933)	-	303
Issuance of common stock on January 20, 2004	15,000	(*)	-	-	-	(*)
Issuance of warrants on January 20, 2004 for finder's fee	-	-	192	-	-	192
Common stock granted to consultants on February 11, 2004	5,000	(*)	800	-	-	800
Stock based compensation related to warrants granted to consultants on December 31, 2003	-	-	358	-	-	358
Exercise of warrants on April 19, 2004	1,500	(*)	225	-	-	225
Net loss for the year	-	-	-	-	(2,011)	(2,011)
Balance as of June 30, 2004	134,793	\$ (*))	\$ 2,909	\$ -	\$ (2,552)	\$ 357

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 6

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	Total
	Shares	Amount	Paid-in	Accumulated	Stockholders'
			Capital	During the	Equity
				Development	(Deficiency)
				Stage	
Balance as of July 1, 2004	134,793	\$ (*))	\$ 2,909	\$ (2,552)	\$ 357
Stock-based compensation related to warrants granted to consultants on September 30, 2004	-	-	162	-	162
Issuance of common stock and warrants on November 30, 2004 related to the October 2004 Agreement net of issuance costs of \$29	16,250	(*)	296	-	296
Issuance of common stock and warrants on January 26, 2005 related to the October 2004 Agreement net of issuance costs of \$5	21,500	(*)	425	-	425
Issuance of common stock and warrants on January 31, 2005 related to the January 31, 2005 Agreement	35,000	(*)	-	-	(*)
Issuance of common stock and options on February 15, 2005 to former director of the Company	250	(*)	14	-	14
Issuance of common stock and warrants on February 16, 2005 related to the January 31, 2005 Agreement	25,000	(*)	-	-	(*)

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 7

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	Total
	Shares	Amount	Paid-in	Accumulated	Stockholders'
			Capital	During the	Equity
				Development	(Deficiency)
				Stage	
Issuance of warrants on February 16, 2005 for finder fee related to the January 31, 2005 Agreement	-	-	144	-	144
Issuance of common stock and warrants on March 3, 2005 related to the January 24, 2005 Agreement net of issuance costs of \$24	60,000	(*)	1,176	-	1,176
Issuance of common stock on March 3, 2005 for finder fee related to the January 24, 2005 Agreement	9,225	(*)	(*)	-	-
Issuance of common stock and warrants on March 3, 2005 related to the October 2004 Agreement net of issuance costs of \$6	3,750	(*)	69	-	69
Issuance of common stock and warrants to the Chief Executive Officer on March 23, 2005	12,000	(*)	696	-	696
Issuance of common stock on March 23, 2005 related to the October 2004 Agreement	1,000	(*)	20	-	20

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 8

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	Total
	Shares	Amount	Paid-in	Accumulated	Stockholders'
			Capital	During the	Equity
				Development	(Deficiency)
				Stage	
Classification of a liability in respect of warrants to additional paid in capital, net of issuance costs of \$ 178	-	-	542	-	542
Net loss for the year	-	-	-	(2,098)	(2,098)
Balance as of June 30, 2005	318,768	(*)	6,453	(4,650)	1,803
Exercise of warrants on November 28, 2005 to finders related to the January 24, 2005 agreement	400	(*)	-	-	-
Exercise of warrants on January 25 ,2006 to finders related to the January 25, 2005 Agreement	50	(*)	-	-	-
Reclassification of warrants from equity to liabilities due to application of ASC 815-40 (originally issued as EITF 00-19)	-	-	(8)	-	(8)
Net loss for the year	-	-	-	(2,439)	(2,439)
Balance as of June 30, 2006	319,218	\$ (*)	\$ 6,445	\$ (7,089)	\$ (644)

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Receipts	Account	Deficit	Total
	Shares	Amount	Paid-in	on	Accumulated	Accumulated	Stockholders'
			Capital	Account	Other	During the	Equity
				of	Loss	Stage	
				Common	Comprehensiv	Development	
				Stock	Development		
Balance as of July 1, 2006	319,218	\$ (*)	\$ 6,445	\$ -	\$ -	\$ (7,089)	\$ (644)
Conversion of convertible debenture, net of issuance costs of \$440	1,019,815	(*)	1,787	-	-	-	1,787
Classification of a liability in respect of warrants	-	-	360	-	-	-	360
Classification of deferred issuance expenses	-	-	(379)	-	-	-	(379)
Classification of a liability in respect of options granted to non-employees consultants	-	-	116	-	-	-	116
Compensation related to options granted to employees and directors	-	-	2,386	-	-	-	2,386
Compensation related to options granted to non-employee consultants	-	-	938	-	-	-	938
Exercise of warrants related to the April 3, 2006 agreement net of issuance costs of \$114	75,692	(*)	1,022	-	-	-	1,022

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Shares	Stock Amount	Additional Paid-in Capital	Receipts on Account of Common Stock	Accumulated Other Comprehensive Loss	Deficit Accumulated During the Development Stage	Total Stockholders' Equity	Total Comprehensive Loss
Cashless exercise of warrants related to the April 3, 2006 agreement	46,674	(*)	(*)	-	-	-	-	
Issuance of common stock on May and June 2007 related to the May 14, 2007 agreement, net of issuance costs of \$64	3,126,177	(*)	7,751	-	-	-	7,751	
Receipts on account of shares	-	-	-	368	-	-	368	
Cashless exercise of warrants related to the May 14, 2007 issuance	366,534	(*)	(*)	-	-	-	-	
Issuance of warrants to investors related to the May 14, 2007 agreement	-	-	651	-	-	-	651	
Unrealized loss on available for sale securities	-	-	-	-	(30)	-	(30)	\$ (30)
Net loss for the year	-	-	-	-	-	(8,429)	(8,429)	(8,429)
Balance as of June 30, 2007	4,954,110	\$ (*)	\$ 21,077	\$ 368	\$ (30)	\$ (15,518)	\$ 5,897	-
Total comprehensive loss								\$ (8,459)

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 11

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Shares	Stock Amount	Additional Paid-in Capital	Receipts on Account of Common Stock	Accumulated Other Comprehensive Loss	Deficit Accumulated During the Development Stage	Total Stockholders' Equity	Total Comprehensive Loss
Balance as of July 1, 2007	4,954,110	\$ (*)	\$ 21,077	\$ 368	\$ (30)	\$ (15,518)	\$ 5,897	
Issuance of common stock related to investors relation agreements	69,500	(*)	275	-	-	-	275	
Issuance of common stock in July 2007 - June 2008 related to the May 14, 2007 Agreement	908,408	(*)	2,246	(368)	-	-	1,878	
Cashless exercise of warrants related to the May 14, 2007 Agreement	1,009,697	(*)	(*)	-	-	-	-	
Compensation related to options granted to employees and directors	-	-	4,204	-	-	-	4,204	
Compensation related to options granted to non-employees consultants	-	-	543	-	-	-	543	
Realized loss on available for sale securities	-	-	-	-	30	-	30	\$ 30
	-	-	-	-	-	(10,498)	(10,498)	(10,498)

Net loss for the
year

Balance as of June 30, 2008	6,941,715	\$ (*)	\$ 28,345	\$ -	\$ -	\$ (26,016)	\$ 2,329
Total comprehensive loss							\$ (10,468)

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 12

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	
	Shares	Amount	Paid-in	Accumulated	Total
			Capital	During the	Stockholders'
				Development	Equity
				Stage	
Balance as of July 1, 2008	6,941,715	\$ (*)	\$ 28,345	\$ (26,016)	\$ 2,329
Issuance of common stock related to investor relations agreements	171,389	(*)	133	-	133
Issuance of common stock and warrants related to the August 6, 2008 agreement, net of issuance costs of \$125	1,391,304	(*)	1,475	-	1,475
Issuance of common stock and warrants related to the September 2008 agreement, net of issuance costs of \$62	900,000	(*)	973	-	973
Issuance of common stock and warrants in November 2008 -January 2009, net of issuance costs of \$39	1,746,575	(*)	660	-	660
Issuance of common stock and warrants related to the January 20, 2009 agreement, net of issuance costs of \$5	216,818	(*)	90	-	90
Issuance of common stock and warrants related to the January 29, 2009 agreement, net of issuance costs of \$90	969,826	(*)	1,035	-	1,035
Issuance of common stock and warrants related to the May 5, 2009 agreement, net of issuance costs of \$104	888,406	(*)	1,229	-	1,229
Compensation related to options granted to employees and directors	-	-	1,315	-	1,315
Compensation related to options and warrants granted to non-employee consultants	-	-	97	-	97
Compensation related to restricted stock granted to	427,228	(*)	642	-	642

employees and directors

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

F - 13

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	Total
	Shares	Amount	Paid-in	Accumulated	Stockholders'
			Capital	During the	Equity
				Development	
				Stage	
Compensation related to restricted stock granted to non-employee consultants	23,625	(*)	52	-	52
Net loss for the period	-	-	-	(6,636)	(6,636)
Balance as of June 30, 2009	13,676,886	\$ (*)	\$ 36,046	\$ (32,652)	\$ 3,394

(*) Less than \$1.

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
(UNAUDITED)

U.S. Dollars in thousands (except share and per share data)

	Common Stock		Additional	Deficit	Total
	Shares	Amount	Paid-in Capital	Accumulated During the Development Stage	Stockholders' Equity
Balance as of July 1, 2009	13,676,886	\$ (*))	\$ 36,046	\$ (32,652)	\$ 3,394
Issuance of common stock related to investor relations agreements	1,929	(*))	12	-	12
Issuance of common stock and warrants related to November 2008 through January 2009 agreements	1,058,708	(*))	794	-	794
Issuance of common stock and warrants related to October 2009 agreements, net of issuance costs of \$242	2,702,822	(*))	2,785	-	2,785
Compensation related to options granted to employees and directors	-	-	166	-	166
Compensation related to options and warrants granted to non-employee consultants	-	-	123	-	123
Exercise of options by employee	3,747	(*))	2	-	2
Compensation related to restricted stock and restricted stock units granted to employees and directors	448,420	(*))	529	-	529
Compensation related to restricted stock and restricted stock units granted to non-employee consultants	21,459	(*))	27	-	27
Net loss for the period	-	-	-	(3,448)	(3,448)
Balance as of December 31, 2009	17,913,971	\$ (*))	\$ 40,484	\$ (36,100)	\$ 4,384

(*) Less than \$1

The accompanying notes are an integral part of the consolidated financial statements.

F - 15

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,		Period from May 11, 2001 (inception) through December 31 2009
	2009	2008	2009
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	\$(3,448)	\$(3,075)	\$(36,100)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	97	84	642
Capital loss	-	-	4
Impairment of property and equipment	-	-	52
Know-how write-off	-	-	2,474
Amortization of deferred issuance costs	-	-	604
Stock-based compensation to employees and directors	695	917	9,242
Stock-based compensation to non-employees consultants	150	27	2,448
Stock compensation to service providers and investor relations consultants	32	63	1,232
Know-how licensors – imputed interest	-	-	55
Salary grant in shares and warrants	-	-	711
Decrease (increase) in other accounts receivable	394	(220)	(91)
Decrease in prepaid expenses	28	167	18
Increase in trade payables	86	4	543
Increase (decrease) in other accounts payable and accrued expenses	67	(129)	(68)
Increase in accrued interest due to related parties	-	-	3
Linkage differences and interest on long-term restricted lease deposit	2	-	-
Change in fair value of liability in respect of warrants	-	-	(2,696)
Fair value of warrants granted to investors	-	-	651
Amortization of discount and changes in accrued interest on convertible debentures	-	-	128
Amortization of discount and changes in accrued interest from marketable securities	-	(3)	(9)
Loss from sale of investments of available-for-sale marketable securities	-	75	106
Impairment and realized loss on available-for-sale marketable securities	-	-	372
Accrued severance pay, net	(5)	5	47
Net cash used in operating activities	\$(1,902)	\$(2,085)	\$(19,632)

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,		Period from May 11, 2001 (inception) through December 31 2009
	2009	2008	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of Pluristem Ltd. (1)	\$-	\$-	\$32
Purchase of property and equipment	(124)	(211)	(1,729)
Investment in short-term deposits	(2,500)	-	(2,500)
Proceeds from sale of property and equipment	-	-	32
Investment in long-term deposits	(7)	(2)	(224)
Repayment of long-term restricted deposit	-	35	64
Purchase of available for sale marketable securities	-	-	(3,784)
Proceeds from sale of available for sale marketable securities	-	1,113	3,314
Purchase of know-how	-	-	(2,062)
Net cash provided by (used in) investing activities	(2,631)	935	(6,857)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Issuance of common stock and warrants, net of issuance costs	3,579	3,028	24,970
Exercise of warrants and options	2	-	1,024
Issuance of convertible debenture	-	-	2,584
Issuance expenses related to convertible debentures	-	-	(440)
Repayment of know-how licensors	-	-	(300)
Repayment of notes and loan payable to related parties	-	-	(70)
Proceeds from notes and loan payable to related parties	-	-	78
Receipt of long-term loan	-	-	49
Repayment of long-term loan	(4)	(8)	(23)
Net cash provided by financing activities	3,577	3,020	27,872
Increase (decrease) in cash and cash equivalents	(956)	1,870	1,383
Cash and cash equivalents at the beginning of the period	2,339	323	-
Cash and cash equivalents at the end of the period	\$ 1,383	\$ 2,193	\$ 1,383

The accompanying notes are an integral part of the consolidated financial statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,		Period from May 11, 2001 (inception) through December 31 2009
	2009	2008	
(a) Supplemental disclosure of cash flow activities:			
Cash paid during the period for:			
Taxes paid due to non-deductible expenses	\$1	\$4	\$49
Interest paid	\$1	\$1	\$18
(b) Supplemental disclosure of non-cash activities:			
Classification of liabilities and deferred issuance expenses into equity	\$-	\$-	\$97
Conversion of convertible debenture	\$-	\$-	\$2,227
Purchase of property and equipment	\$43	\$-	\$43
Issuance of shares in consideration of accounts receivable	\$-	\$44	\$-
(1) Acquisition of Pluristem Ltd.			
Fair value of assets acquired and liabilities assumed at the acquisition date:			
Working capital (excluding cash and cash equivalents)			\$(427)
Long-term restricted lease deposit			19
Property and equipment			130
In-process research and development write-off			246
			\$(32)

The accompanying notes are an integral part of the consolidated financial statements.

F - 18

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 1: - GENERAL

a. Pluristem Therapeutics Inc. ("the Company"), a Nevada corporation, was incorporated and commenced operations on May 11, 2001, under the name A. I. Software Inc. which was changed as of June 30, 2003 to Pluristem Life Systems Inc. On November 26, 2007, the Company's name was changed to Pluristem Therapeutics Inc. The Company has a wholly owned subsidiary, Pluristem Ltd. ("the Subsidiary"), which is incorporated under the laws of Israel.

b. The Company is devoting substantially all of its efforts towards conducting research and development of adherent stromal cells production technology and the commercialization of cell therapy products. Accordingly, the Company is considered to be in the development stage, as defined in Accounting Standards Codification TM ("ASC") 915 (originally issued as Statement of Financial Accounting Standards ("FAS") No. 7, "Accounting and Reporting by Development stage Enterprises"). In the course of such activities, the Company and its Subsidiary have sustained operating losses and expect such losses to continue in the foreseeable future. The Company and its Subsidiary have not generated any revenues or product sales and have not achieved profitable operations or positive cash flows from operations. The Company's accumulated losses during the development stage aggregated to \$36,100 through December 31, 2009 and incurred net loss of \$3,448 and negative cash flow from operating activities in the amount of \$1,902 for the six months ended December 31, 2009. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis.

The Company plans to continue to finance its operations with sales of equity securities and research and development grants and in the longer term, from revenues from product sales or licensing of its technology. There are no assurances, however, that the Company will be successful in obtaining an adequate level of financing needed for the long-term development and commercialization of its planned products.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

c. Since December 10, 2007, the Company's shares of common stock have been traded on the NASDAQ Capital Market under the symbol PSTI. The shares were previously traded on the OTC Bulletin Board under the trading symbol "PLRS.OB". On May 7, 2007, the Company's shares also began trading on Europe's Frankfurt Stock Exchange, under the symbol PJT.

d. The Company evaluated all events or transactions that occurred after December 31, 2009 up through February 11, 2010. No subsequent events occurred until the filing date, February 11, 2010.

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

A. The accompanying unaudited interim financial statements of Pluristem Therapeutics Inc., a development stage company, have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the

Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 10-Q

audited financial statements and notes thereto contained in Pluristem's latest Annual Report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year as reported in Form 10-K have been omitted.

F - 19

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

B. Impact of recently issued accounting standards:

In June 2009, the Financial Accounting Standards Board ("FASB") issued ASC 105-10-65-1 ("ASC 105") (originally issued as FAS 168, "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles", a replacement of SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles"). ASC 105 is effective for financial statements for interim and annual periods ending after September 15, 2009. ASC 105 establishes the FASB Accounting Standards Codification ("Codification") as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with Generally Accepted Accounting Principles. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates ("ASU"). The ASU will not be authoritative in their own right as they will only serve to update the Codification. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on the Company's Financial Statements. The Company has adopted ASC 105 and therefore all references by the Company to authoritative accounting principles recognized by the FASB reflect the Codification.

In August 2009, the FASB issued ASU No. 2009-05 "Fair Value Measurements and Disclosures (Topic 820) - Measuring Liabilities at Fair Value" ("ASU 2009-05"). ASU 2009-05 amends Subtopic 820-10 "Fair Value Measurements and Disclosures - Overall" and provides clarification on the methods to be used in circumstances in which a quoted price in an active market for the identical liability is not available. The provisions of ASU 2009-05 were effective for the third quarter of 2009. The adoption of ASU 2009-05 did not have a material impact on the Company's financial statements.

In June 2009, the FASB issued ASU No. 15-1- "Accounting for Own-Share Lending Arrangements in Contemplation of Convertible Debt Issuance or Other Financing" ("ASU 15-1") (formerly issued as EITF 09-1). ASU 15-1 states that a share-lending arrangement entered into on an entity's own shares in contemplation of a convertible debt offering or other financing is required to be measured at fair value and recognized as a debt issuance cost in the financial statements. The debt issuance costs should be amortized using the effective interest method over the life of the financing arrangement as interest cost. In addition, the loaned shares should be excluded from the computations of basic and diluted earnings per share, unless default of the share-lending arrangement occurs, at which time the loaned shares would be included in the basic and diluted earnings per share calculation. ASU 15-1 also expanded the disclosure requirements for share-lending arrangements. ASU 15-1 is effective from January 1, 2010. Early adoption was not permitted. Retrospective application is required for all arrangements outstanding in the beginning of the fiscal year in which this Issue is initially applied. The Company is currently assessing the impact of ASU 15-1 on the Company's financial statements.

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS

a. On December 22, 2009, the Company's authorized common stock was increased from 30,000,000 shares with a par value of \$0.00001 per share to 100,000,000 shares with a par value of \$0.00001 per share. All shares have equal voting rights and are entitled to one vote per share in all matters to be voted upon by stockholders. The shares have no pre-emptive, subscription, conversion or redemption rights and may be issued only as fully paid and non-assessable shares. Holders of the common stock are entitled to equal ratable rights to dividends and

distributions with respect to the common stock, as may be declared by the Board of Directors out of funds legally available.

On July 1, 2008, the authorized share capital of the Company was increased by authorizing 10,000,000 shares of preferred stock, par value \$0.00001 each, with series, rights, preferences, privileges and restrictions as may be designated from time to time by the Company's Board of Directors. No shares of preferred stock have been currently issued.

F - 20

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS

- b. On July 9, 2001, the Company issued 175,500 shares of common stock in consideration for \$2.50, which was received on July 27, 2001.
- c. On October 14, 2002, the Company issued 70,665 shares of common stock at a price of approximately \$1.4 per common share in consideration for \$100 before issuance costs of \$17. On March 19, 2003, two directors each returned 68,250 shares of common stock with a par value of \$2 per share, for cancellation, for no consideration.
- d. In July 2003, the Company issued an aggregate of 3,628 units comprised of 3,628 shares of common stock and 7,256 warrants to a group of investors, for total consideration of \$1,236 (net of issuance costs of \$70), under a private placement. The consideration was paid partly in the year ended June 30, 2003 (\$933) and the balance was paid in the year ended June 30, 2004.

In this placement each unit was comprised of one share of common stock and two warrants, the first warrant was exercisable within a year from the date of issuance for one share of common stock at a price of \$450 per share. The second warrant is exercisable within five years from the date of issuance for one share of common stock at a price of \$540 per share. All the warrants expired unexercised.

- e. On January 20, 2004, the Company consummated a private equity placement with a group of investors (the "Investors"). The Company issued 15,000 units in consideration for net proceeds of \$1,273 (net of issuance costs of \$227). Each unit is comprised of 15,000 shares of common stock and 15,000 warrants. Each warrant is exercisable into one share of common stock at a price of \$150 per share, and may be exercised until January 31, 2007. On March 18, 2004, a registration statement on Form SB-2 was declared effective and the above-mentioned common stock was registered for re-sale. If the effectiveness of the Registration Statement is suspended subsequent to the effective date of registration (March 18, 2004), for more than certain permitted periods, as described in the private equity placement agreement, the Company shall pay penalties to the Investors in respect of the liquidated damages.

According to ASC 815-40 (originally issued as Emerging Issued Task Force ("EITF") 00-19, "Accounting for derivative financial instruments indexed to, and potentially settled in, a Company's own stock" ("EITF 00-19")), the Company classified the warrants as liabilities according to their fair value as remeasured at each reporting period until exercised or expired. Changes in the fair value of the warrants were reported in the statements of operations as financial income or expense.

The Company allocated the gross amount received of \$1,500 to the par value of the shares issued (\$0.03) and to the liability in respect of the warrants issued (\$1,499.97). The amount allocated to the liability was less than the fair value of the warrants at grant date. On January 31, 2007 all the warrants expired unexercised.

In addition, the Company issued 1,500 warrants to finders in connection with this private placement, exercisable into 1,500 common shares at a price of \$150 per common share until January 31, 2007. The fair value of the warrants issued in the amounts of \$192 was recorded as deferred issuance costs and is amortized over a period of three years. On April 19, 2004, the finders exercised the warrants.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

f. In October 2004, the Company consummated a private placement offering (“the October 2004 Agreement”) pursuant to which it issued 42,500 units. Each unit is comprised of one common stock and one warrant. The warrant is exercisable for one common stock at an exercise price of \$60 per share, subject to certain adjustments. The units were issued as follows:

In November 2004, the Company issued according to the October 2004 Agreement 16,250 units comprised of 16,250 shares of common stock and 16,250 warrants to a group of investors, for total consideration of \$296 (net of cash issuance costs of \$29), and additional 600 warrants to finders as finders’ fees.

In January 2005, the Company issued according to the October 2004 Agreement an additional 21,500 units for total consideration of \$425 (net of cash issuance costs of \$5), and additional 450 warrants were issued to finders as finders’ fees.

In March 2005, the Company issued according to the October 2004 Agreement additional 3,750 units for total consideration of \$69 (net of cash issuance costs of \$6), and additional 175 warrants were issued to finders as finders’ fees.

In March 2005, the Company issued according to the October 2004 Agreement 1,000 common shares and 1,000 share purchase warrants to one investor for total consideration of \$20 which was paid to the Company in May 2005.

On November 30, 2006, all the warrants expired unexercised.

g. On January 24, 2005, the Company consummated a private placement offering (the “January 24, 2005 Agreement”) which was closed on March 3, 2005 and issued 60,000 units in consideration for \$1,176 (net of cash issuance costs of \$24). Each unit is comprised of one share of common stock and one warrant. The warrant is exercisable for one share of common stock at a price of \$60 per share. On November 30, 2006, all the warrants expired unexercised. Under this agreement the Company issued to finders 9,225 shares and 2,375 warrants with exercise price of \$500 per share exercisable until November 2007. On November 30, 2007, 1,925 unexercised warrants expired.

h. On January 31, 2005, the Company consummated a private equity placement offering (the “January 31, 2005 Agreement”) with a group of investors according to which it issued 60,000 units in consideration for net proceeds of \$1,137 (net of issuance costs of \$63). Each unit is comprised of one share of common stock and one warrant. Each warrant is exercisable into one share of common stock at a price of \$60 per share. The January 31, 2005 Agreement includes a finder’s fee of a cash amount equal to 5% of the amount invested (\$60) and issuance of warrants for number of shares equal to 5% of the number of shares that were issued (3,000) with an exercise price of \$20 per share, subject to certain adjustments, exercisable until November 30, 2006.

According to ASC 815-40 (originally issued as EITF 00-19), the Company classified the warrants as liabilities according to their fair value as remeasured at each reporting period until exercised or expired. Changes in the fair value of the warrants will be reported in the statements of operations as financial income or expense.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

As of the date of the issuance, the Company allocated the gross amount received of \$1,200 to the par value of the shares issued (\$0.12) and to the liability in respect of the warrants issued (\$1,200). Issuance expenses in the amount of \$63 and finders fee in the amount of \$144 were recorded as deferred issuance costs. The amount allocated to the liability was less than the fair value of the warrants at grant date. On May 13, 2005, the Registration Statement became effective and the Company was no longer subject to possible penalties. As such, the liability and the deferred issuance costs related to the agreement has been classified to the Stockholders Equity as Additional Paid in Capital. As of May 13, 2005, the fair value of the liability in respect of the warrants issued was \$720 and the amount of the deferred issuance costs was \$178.

On November 30, 2006, all the warrants expired unexercised.

i. On March 23, 2005, the Company issued 12,000 shares of common stock and 12,000 options as a bonus to the then Chief Executive Officer, Dr. Shai Meretzki, in connection with the issuance of a Notice of Allowance by the United States Patent Office for patent application number 09/890,401. Salary expenses of \$696 were recognized in respect of this bonus based on the quoted market price of the Company's stock and the fair value of the options granted using the Black-Scholes valuation model. On November 30, 2006, all the warrants expired unexercised.

j. On February 11, 2004, the Company issued an aggregate amount of 5,000 shares of common stock to a consultant and service provider as compensation for carrying out investor relations activities during the year 2004. Total compensation, measured as the grant date fair market value of the stock, amounted to \$800 and was recorded as an operating expense in the statement of operations in the year ended June 30, 2004.

k. On November 28, 2005, 400 warrants, which were issued to finders as finder fees related to the January 24, 2005 Agreement, were exercised.

l. On January 25, 2006, 50 warrants, which were issued to finders as finder fees related to the January 24, 2005 Agreement, were exercised.

m. Convertible Debenture

On April 3, 2006, the Company issued Senior Secured Convertible Debentures (the "Debentures"), for gross proceeds of \$3,000. In conjunction with this financing, the Company issued 236,976 warrants exercisable for three years at an exercise price of \$15 per share. The Company paid a finder's fee of 10% in cash and issued 47,394 warrants exercisable for three years, half of which are exercisable at \$15 and half of which are exercisable at \$15.4 per share. The Company also issued 5,000 warrants in connection with the separate finder's fee agreement related to the issuance of the debenture exercisable for three years at an exercise price of \$15 per share.

- a. Interest accrued on the Debentures at the rate of 7% per annum, was payable semi-annually on June 30 and December 31 of each year and on conversion and at the maturity date. Interest was payable, at the option of the Company, either (1) in cash, or (2) in shares of common stock at the then applicable conversion price. If the Company failed to deliver stock certificates upon the conversion of the Debentures at the specified time and in the specified manner, the Company was required to make substantial payments to the holders of the Debentures.

- b. The warrants, issued as of April 3, 2006, become first exercisable on the 65th day after issuance. Holders of the warrants were entitled to exercise their warrants on a cashless basis following the first anniversary of issuance if the Registration Statement is not in effect at the time of exercise.

F - 23

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

m. Convertible Debenture (Cont.):

In accordance with ASC 815-40 (originally issued as EITF 00-19), the Company allocated the consideration paid for the convertible debenture and the warrants as follows:

The warrants were recorded as a liability based on their fair value in the amount of \$951 at grant date. The Company estimated the fair value of the warrants using a Black-Scholes option pricing model, with the following assumptions: volatility of 83%, risk free interest rate of 4.8%, dividend yield of 0%, and an expected life of 36 months. Changes in the fair value are recorded as interest income or expense, as applicable.

The fair value of the conversion feature of the debentures at grant date, in the amount of \$1,951 was recorded as a liability.

The balance of the consideration, in the amount of \$97, was allocated to the debentures. The discount in the amount of \$2,903 was amortized according to the effective rate interest method over the debentures contractual period (24 months).

The fair value of the warrants issued as a finder's fee and the finder's fee in cash amounted to \$535 and were recorded as deferred issuance expenses and are amortized over the Debentures' contractual period. The Company estimated the fair value of the warrants using a Black - Scholes option pricing model, with the following assumptions: volatility of 83%, risk free interest rate of 4.8%, dividend yield of 0%, and an expected life of 36 months.

According to ASC 815-40 (originally issued as EITF 00-19), in order to classify warrants and options (other than employee stock options) as equity and not as liabilities, the Company should have sufficient authorized and unissued shares of common stock to provide for settlement of those instruments that may require share settlement. Under the terms of the Debentures, the Company may be required to issue an unlimited number of shares to satisfy the debenture's contractual requirements. As such, on April 3, 2006, the Company's warrants and options (other than employee stock options) were classified as liabilities and measured at fair value with changes recognized currently in earnings.

As of November 9, 2006, all of the Debentures, were converted into 969,815 shares. As a result, an amount of \$1,787 was reclassified into common stock and additional paid-in capital as follows: from conversion of the feature embedded in convertible debenture (\$1,951), convertible debenture (\$202), accrued interest (\$74) net of issuance expenses in the amount of \$440. In addition, the warrants and options to consultants in the amount of \$476 and deferred issuance expenses in the amount of \$379 were reclassified as equity.

Pursuant to an investor relations agreement dated April 28, 2006, the Company paid in cash an amount of \$440 on October 19, 2006 and issued 50,000 common shares on November 9, 2006 to certain service providers following reaching certain milestones regarding the conversion of the Debentures as agreed to by the parties.

During the year ended June 30, 2007, 186,529 of the warrants which were issued on April 3, 2006, were exercised. 75,692 warrants were exercised into shares in consideration for \$1,022 (net of cash exercise costs of \$114), and

110,836 warrants were exercised cashless into 46,674 shares. On April 30, 2009, the rest of the warrants expired unexercised.

F - 24

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

n. On May 14, 2007, the Company consummated a private equity placement with a group of investors for an equity investment ("May 2007 Agreement"). The Company sought a minimum of \$7,000 and up to a maximum of \$13,500 for shares of the Company's common stock, \$.00001 par value at a per share price of \$2.50, and warrants to purchase shares at an exercise price of \$5 exercisable until five years after the closing date of the agreement.

In May 2007, under the May 2007 Agreement, the Company issued 3,126,177 shares of the Company's common stock and 3,126,177 warrants to purchase the Company's common stock in consideration for \$7,751 (net of cash issuance costs of \$64).

During July and August 2007, under the May 2007 Agreement, the Company issued additional 273,828 shares of the Company's common stock and 273,828 warrants to purchase the Company's common stock in consideration for \$685. The consideration was paid partly prior to the issuance of the shares in the year ended June 30, 2007 (\$368) and was recorded as receipts on account of shares and the balance was paid during July and August 2007.

As part of May 2007 Agreement, the Company signed an escrow agreement according to which the Company granted an option to an investor to invest, under the same conditions defined in the May 2007 Agreement, up to \$5,000 which will be paid in monthly installments over 10 months starting six months subsequent to the closing date. According to the agreement, in the event that the investor fails to make any of the payments within five days of the payment due date, the option to invest the remaining amount will be cancelled. As a result of this agreement, the Company issued 634,580 shares of the Company's common stock and 634,580 warrants to purchase the Company's common stock in consideration for \$1,561 (net of cash issuance costs of \$25). As of March 31, 2008 the option was cancelled.

The total proceeds related to the May 2007 Agreement accumulated as of June 30, 2008 were \$9,997 (net of cash issuance costs of \$89), and 4,034,585 shares and 4,034,585 warrants were issued.

In connection with the May 2007 Agreement, the Company issued 275,320 warrants to finders as finders' fee. The warrants are exercisable for five years from the date of grant at an exercise price of \$2.50 per share.

During 2008 and 2007, 1,361,818 and 500,000 warrants related to the May 2007 Agreement were exercised on a cashless basis for 1,009,697 shares of stock and 366,534 shares of stock, respectively.

o. The Company issued 28,398 warrants to the investors related to the May 2007 Agreement as compensation to investors who delivered the invested amount prior to the closing date of the placement. The warrants are exercisable for five years at an exercise price of \$2.50 per share. The Company recorded the fair value of the warrants as financial expenses in the amount of \$651 in the year ended June 30, 2007. The fair value of these warrants was determined using the Black-Scholes pricing model, assuming a risk free rate of 4.8%, a volatility factor of 128%, dividend yield of 0% and expected life of five years.

p. In the May 2007 Agreement, there is a provision that requires the Company for a period of four years (subject to acceleration under certain circumstances) not to sell any of the Company's common stock for less than \$0.0125 per share (pre-split price). The May 2007 Agreement provides that any sale below that price must be preceded by consent from each purchaser in the placement. Since that date, the Company had effected a one-for-200 reverse

stock split.

F - 25

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

p. (Cont.):

The Company decided to proceed and enter into additional security purchase agreements notwithstanding this provision for the following reasons:

- The agreement does not contain any provisions for the adjustment of the specified minimum price in the event of stock splits and the like. If such agreement were to have contained such a provision, the floor price would be \$2.50.
- The majority of purchasers in the private placement have sold the stock purchased in the placement, and thus the number of purchasers whose consent is purportedly required has been substantially reduced. The number of shares outstanding as to which this provision currently applies according to the information supplied by transfer agent is 1.8 million shares.
- An agreement that prevents the Company's Board of Directors from issuing shares that are necessary to finance the Company's business may be unenforceable.

It is unclear what could be the consequences of a court decision that the issuance of shares below \$2.50 per share violates the May 2007 Agreement.

In connection therewith, the Company approved the issuance of warrants to purchase up to 147,884 shares of its common stock to each of the investors who was a party to the May 2007 Agreement that held shares purchased pursuant to such agreement, as of August 6, 2008, conditioned on having the investors execute a general release pursuant to which the Company will be released from liability including, but not limited to, any claims, demands, or causes of action arising out of, relating to, or regarding sales of certain equity securities notwithstanding the above mentioned provision. As of December 31, 2009 the Company received a general release from part of the investors, and issued them warrants to purchase 70,368 shares of its common stock.

q. On August 6, 2008, the Company sold 1,391,304 shares of the Company's common stock and warrants to purchase 695,652 shares of common stock at an exercise price of \$1.90 to two investors in consideration of \$1,600 pursuant to terms of a securities purchase agreement. The placement agent received a placement fee equal to 6% of the gross purchase price of the Units (excluding any consideration that may be paid in the future upon exercise of the warrants) as well as warrants to purchase 83,478 shares of common stock at an exercise price of \$1.44 per share. The warrants will be exercisable after six months from the closing date through and including August 5, 2013. Total cash issuance costs related to this placement amounted to \$125.

r. On September 22, 2008, the Company sold 900,000 shares of the Company's common stock and warrants to purchase 675,000 shares of common stock to an investor in consideration for \$1,035 pursuant to terms of a securities purchase agreement. The price per share of common stock was \$1.15, and the exercise price of the warrants is \$1.90. The warrants will be exercisable for a period of five years. As part of this transaction, the Company paid a transaction fee to the finders equal to 6% of the actual purchase price and warrants exercisable for five years at an exercise price of \$1.50 per share to purchase 54,000 of the Company's shares of common stock. Total cash issuance costs related to this placement amounted to \$62.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

s. From November 2008 through January 2009, the Company entered into a securities purchase agreement with investors, pursuant to which the Company sold 1,746,575 shares of its common stock at a price of \$0.40 per share, for an aggregate purchase price of \$699, and issued warrants to purchase up to an additional 1,746,575 shares of common stock with an exercise price of \$1.00 per share. The warrants will be exercisable after six months from the closing date and will expire after five years. Pursuant to the agreement, the investors have the option, by notice to the Company no later than 10 business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, to purchase an additional 931,507 shares of common stock at a purchase price of \$0.75 per share, for an aggregate purchase price of \$699, and receive therewith warrants to purchase up to an additional 931,507 shares of common stock with an exercise price of \$1.50 per share.

The issuance costs include \$39 in cash and warrants exercisable for five years at an exercise price of \$1.00 per share to purchase 96,579 of the Company's shares of common stock.

t. On January 20, 2009, the Company sold 216,818 shares of its common stock and warrants to purchase 216,818 shares of common stock to investors in consideration for \$95 pursuant to terms of a securities purchase agreement. The price per share of common stock is \$0.44, and the exercise price of the warrants is \$1.00 per share. The warrants will be exercisable after six months from the closing date and will expire after five years. Pursuant to the agreement, the investors have the option, by notice to the Company no later than 10 business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, to purchase an additional 127,200 shares of common stock at a purchase price of \$0.75 per share, for an aggregate purchase price of \$95, and receive therewith warrants to purchase up to an additional 127,200 shares of common stock with an exercise price of \$1.50 per share (the "January 20 Option"). The January 20 Option is exercisable within six months from the closing date. As part of this transaction, the Company paid a transaction fee to finders in an amount of \$5 in cash and issued them warrants exercisable for two years at an exercise price of \$1.00 per share to purchase 12,273 shares of the Company's common stock.

u. On January 29, 2009, the Company entered into a subscription agreement with certain investors, pursuant to which the Company sold to such investors 969,826 units, each unit consisting of one share of common stock and a warrant to purchase one of the Company's share of common stock ("Unit"). The purchase price per Unit was \$1.16 and the aggregate purchase price for the said Units was approximately \$1,125. The warrants are exercisable 181 days following the issuance thereof for a period of five years thereafter at an exercise price of \$1.90 per share. The Company paid a transaction fee to finders in an amount of \$90 in cash and issued them warrants exercisable after six months for five years at an exercise price of \$1.90 per share to purchase 80,983 shares of the Company's common stock.

v. On May 5, 2009, the Company entered into securities purchase agreements with two investors pursuant to which the Company sold 888,406 shares of its common stock and warrants to purchase 488,623 shares of common stock in consideration for \$1,333. The exercise price of the warrants is \$1.96 per share and they will be exercisable for a period of five years commencing six months following the issuance thereof.

The Company paid a transaction fee to finders in an amount of \$104 in cash and issued them warrants exercisable after six months for five years at an exercise price of \$1.875 per share to purchase 53,304 shares of the Company's common stock.

w. On July 7, 2009, the Company announced that the first patient has been enrolled in a Phase I clinical trial of its PLX-PAD product. Upon the occurrence of such event, certain investors had an option from prior agreements from November 2008 through January 2009 to purchase additional shares and warrants. Accordingly, certain investors purchased in July 2009, 1,058,708 shares of common stock at a purchase price of \$0.75 per share, for an aggregate purchase price of \$794, and warrants to purchase up to an additional 1,058,708 shares of common stock with an exercise price of \$1.50 per share. The warrants will be exercisable for a period of 4 years and six months commencing six months following the issuance.

F - 27

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

x. On October 12, 2009, certain institutional investors purchased 2,702,822 shares of the Company's common stock and warrants to purchase 1,081,129 shares of Common Stock. The price per share of common stock was \$1.12, and the exercise price of the warrants was \$1.60 per share. The warrants will be exercisable for a period of five years commencing six months following the issuance thereof. The gross proceeds received from this offering were approximately \$3,027. Total cash costs related to this placement amounted to \$242.

y. The following table summarizes the issuance of shares to the Company's consultants and service providers as compensation for their services since July 1, 2007:

Period of service	Number of shares issued	Fair market value of the shares issued at the date	Expenses in the statements of operations for the		
			year ended June 30, 2008	year ended June 30, 2009	six months ended December 31, 2009
June – December 2007	10,000	149	149	-	-
February – July 2008	7,500	18	18	-	-
March - September 2008	3,500	8	6	2	-
April – June 2008	50,000	102	102	-	-
July 2008 – June 2009	16,129	10	-	10	-
July –September 2008	40,000	46	-	46	-
October 2008	750	1	-	1	-
October 2008	20,000	12	-	12	-
December 2008 – November 2009	50,000	24	-	14	10
February – July 2009	11,439	14	-	12	2
February – April 2009	30,000	32	-	32	-
April 2009	3,500	4	-	4	-
Total	242,818	420	275	133	12

The issuance of shares to the consultants was in some cases in addition to cash compensation the consultants were entitled to.

In July 2009, the Company entered into an investor relations agreement pursuant to which the service will be provided to the Company in consideration for a cash retainer and a monthly issuance of shares of common stock of the Company, beginning September 1, 2009. Since the shares were not issued yet, the Company recorded a liability in the amount of the fair value of the shares, which amounted to \$20.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

z. Options, warrants, restricted stock and restricted stock units to employees, directors and consultants:

The Company has approved two incentive option plans from 2003 and from 2005 (the "Plans"). Under these plans, options, restricted stock and restricted stock units (the "Awards") may be granted to the Company's officers, directors, employees and consultants or the officers, directors, employees and consultants of the Subsidiary.

Each option granted under the plan adopted in 2005, as it was amended and restated on January 21, 2009 (the "2005 Plan") is exercisable through the expiration date of the 2005 Plan, which is December 31, 2018, unless stated otherwise. The Awards vest over two years from the date of grant, as follows: 25% vests six months after the date of grant, and the remaining Awards vest monthly, in equal instalments over 18 months unless other vesting schedules are specified. Any Awards that are cancelled or forfeited before expiration become available for future grants.

As of December 31, 2009, the number of Shares authorized for issuance under the 2005 Plan amounted to 5,178,565. 266,686 Shares are still available for future grant under the 2005 Plan as of December 31, 2009. Under the 2003 Plan 12,757 options are still available for future grant.

a. Options to employees and directors:

The Company accounted for its options to employees and directors under the fair value method in accordance with ASC 718 (originally issued as SFAS 123(R) "Share-Based Payment"). A summary of the Company's share option activity for options granted to employees and directors under the Plans is as follows:

	Number	Weighted Average Exercise Price	Six months ended December 31, 2009	
			Weighted Average Remaining Contractual Terms (in years)	Aggregate Intrinsic Value Price
Options outstanding at beginning of period	2,366,106	\$3.72		
Options exercised	(3,747)	0.62		
Options forfeited	(5,544)	4.85		
Options outstanding at end of the period	2,356,815	\$3.72	7.39	\$322
Options exercisable at the end of the period	2,084,413	\$4.12	7.20	\$188
Options vested and expected to vest	2,350,069	\$3.74	7.38	\$316

F - 29

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

z. Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

a. Options to employees and directors (cont.):

Intrinsic value of exercisable options (the difference between the Company's closing stock price on the last trading day in the period and the exercise price, multiplied by the number of in-the-money options) represents the amount that would have been received by the employees and directors option holders had all option holders exercised their options on December 31, 2009. This amount changes based on the fair market value of the Company's stock.

Compensation expenses related to options granted to employees and directors were recorded as follows:

	Six months ended December 31,		Three months ended December 31,		Period from inception through December 31,
	2009	2008	2009	2008	2009
Research and development expenses	\$ 52	\$ 259	\$ 20	\$ 101	\$ 2,559
General and administrative expenses	114	602	42	240	5,512
	\$ 166	\$ 861	\$ 62	\$ 341	\$ 8,071

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

z. Options, warrants, restricted stocks and restricted stock units to employees, directors and consultants (cont.):

b. Options and warrants to non-employees:

On July 17, 2009, the Company granted 90,000 options exercisable at a price of \$0.00001 per share to Company consultants under the 2005 Plan. The fair value of these options at the grant date was \$116. The fair value was estimated using Black-Scholes option-pricing model with the following assumptions: risk-free interest rates of 3.59%, expected dividend yield of 0%, expected volatility of 136%, and a weighted-average contractual life of the options of 10 years.

A summary of the Company's activity related to options and warrants to consultants is as follows:

	Six months ended December 31, 2009			
	Number	Weighted Average Exercise Price	Weighted Average Remaining Contractual Terms (in years)	Aggregate Intrinsic Value Price
Options and warrants outstanding at beginning of period	336,000	\$5.48		
Options and warrants granted	90,000	\$(*)		
Options and warrants forfeited	-	-		
Options and warrants outstanding at end of the period	426,000	\$4.32	4.94	\$110
Options and warrants exercisable at the end of the period	294,337	\$6.05	3.99	\$3
Options and warrants vested and expected to vest	426,000	\$4.32	4.94	\$110

(*) Par value of \$0.00001 per share.

Compensation expenses related to options and warrants granted to consultants were recorded as follows:

	Six months ended		Three months ended		Period from inception through December 31 2009
	2009	2008	2009	2008	
Research and development expenses	\$61	\$5	\$31	\$1	\$ 1,577
General and administrative expenses	62	22	19	3	792
	\$123	\$27	\$50	\$4	\$ 2,369

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

z. Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

c. Restricted stock and restricted stock units to employees and directors:

On December 22, 2009, the Company granted 1,060,000 restricted stock units to the Company's employees and directors under the 2005 Plan. The purchase price is \$0.00001 per share. The fair value of these shares at the grant date was \$1,049.

The following table summarizes the activities for unvested restricted stock units and restricted stocks granted to employees and directors for the six months ended December 31, 2009:

	Number
Unvested at the beginning of period	1,012,171
Granted	1,060,000
Vested	(448,420)
Unvested at the end of the period	1,623,751
Expected to vest after December 31, 2009	1,580,300

Compensation expenses related to restricted stock and restricted stock units granted to employees and directors were recorded as follows:

	Six months ended December 31,		Three months ended December 31,		Period from inception through December 31,
	2009	2008	2009	2008	2009
Research and development expenses	\$ 204	\$ 22	\$ 84	\$ 22	\$ 454
General and administrative expenses	325	34	147	34	717
	\$ 529	\$ 56	\$ 231	\$ 56	\$ 1,171

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

z. Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

d. Restricted stock and restricted stock units to consultants:

On December 22, 2009, the Company granted 80,000 restricted stock units to the Company's consultants under the 2005 Plan. The purchase price is \$0.00001 per share. The fair value of these shares at the grant date was \$79.

The following table summarizes the activities for unvested restricted stock units and restricted stocks granted to consultants for the six months ended December 31, 2009:

	Number
Unvested at the beginning of period	49,636
Granted	80,000
Vested	(21,459)
Unvested at the end of the period	108,177
Expected to vest after December 31, 2009	108,177

Compensation expenses related to restricted stock and restricted stock units granted to consultants were recorded as follows:

	Six months ended		Three months ended		Period
	December 31,		December 31,		from inception
	2009	2008	2009	2008	through
					December
					31,
					2009
Research and development expenses	\$ 27	\$ -	\$ 10	\$ -	\$ 79
General and administrative expenses	-	-	-	-	-
	\$ 27	\$ -	\$ 10	\$ -	\$ 79

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except per share amounts)

NOTE 3: - SHARE CAPITAL AND STOCK OPTIONS (CONT.)

aa. Summary of warrants and options:

A summary of all the warrants and options outstanding as of December 31, 2009 is presented in this table:

Warrants / Options	Exercise Price per Share	Options and Warrants for Common Stock	Options and Warrants Exercisable	Weighted Average Remaining Contractual Terms
Warrants:	\$1.00	2,072,245	2,072,245	3.90
	\$1.40 - \$			
	1.50	1,196,186	137,478	4.49
	\$1.60	1,081,129	-	5.28
	\$1.80 - \$			
	2.00	3,126,272	3,126,272	3.98
	\$2.50	131,898	131,898	1.66
	\$4.40	3,750	3,750	0.80
	\$5.00	2,394,585	2,394,585	2.49
Total warrants		10,006,065	7,866,228	
Options:	\$0.00	90,000	-	9.54
	\$0.62	586,253	340,491	8.83
	\$1.04	93,750	62,946	8.57
	\$1.34	100,000	66,668	4.32
	\$2.97	20,000	15,833	8.36
	\$3.50	1,021,491	1,021,491	6.53
	\$3.72 - \$			
	3.80	36,116	36,116	6.28
	\$4.00	42,500	42,500	6.80
	\$4.38 - \$			
	4.40	481,239	481,239	7.44
	\$6.80	36,250	36,250	7.87
	\$8.20	48,547	48,547	6.65
	\$20.00	157,919	157,919	6.71
Total options		2,714,065	2,310,000	
Total warrants and options		12,720,130	10,176,228	

This summary does not include 591,928 shares of restricted stock and 1,140,000 RSUs that are not vested as of December 31, 2009.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward - Looking Statements

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Such forward-looking statements appear in this Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations," and include statements regarding our expectations, regarding our capital requirements, our plans to raise additional funding, including non-dilutive funding, statements regarding the clinical trials we started and statements about the potential safety and efficacy of our PLX-PAD product. Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this report. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

Our financial statements are stated in thousands United States Dollars (U.S.\$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars.

As used in this quarterly report, the terms "we", "us", "our", the "company" and "Pluristem" mean Pluristem Therapeutics Inc. and our wholly owned subsidiary, Pluristem Ltd., unless otherwise indicated or as otherwise required by the context.

Overview

We develop and intend to commercialize cell therapy production technologies and products. In June and September 2009 we commenced enrollment of patients in two Phase I clinical trials of our placenta expanded cells product for treatment of peripheral artery disease, also referred to as the PLX-PAD product, in Germany and the US respectively. Both trials are open label dose escalating trials. The trial in Germany will enroll up to a total of fifteen patients and utilize three doses while the US trial will enroll up to a total of twelve patients and utilize two doses.

Currently, there are three clinical sites actively recruiting patients, one in Germany and two in the US.

On January 11, 2010 we announced initial results from PLX-PAD clinical trials whereby nine patients, representing one-third of the patients needed to complete the Phase I dose-escalating studies in the U.S. and Germany, have been dosed with our PLX-PAD product. Patients experienced no significant unfavorable effects related to PLX-PAD administration. Three of the nine patients dosed completed their three-month follow up and the data from those patients demonstrated a trend towards efficacy with a reduction in their Rutherford Category, a measure of the severity of their limb ischemia. To date, 13 patients have been enrolled to the clinical trial.

We have not generated revenues since our inception. Historically to fund our operations, we have relied on private placement issuances and public offerings of equity, as well as on governmental grants.

We do not expect to generate revenues from sales of products in the next 12 months, and therefore it is likely that we will need to raise additional working capital to fund our ongoing operations and growth. Cash used for operations will be affected by numerous known and unknown risks and uncertainties including, but not limited to, our ability to successfully develop and commercialize our products and the degree to which competitive products are introduced to the market. Our products will likely not be ready for sale for at least three years, if at all. We believe that the funds we have, together with an approved R&D grant from the Israeli Office of Chief Scientist (the "OCS"), will be sufficient for operating until at least September 2010. As long as our cash flow from operations remains insufficient to fund operations, we will continue depleting our financial resources and seeking additional capital through equity financing and governmental grants. If we raise additional funds through the issuance of equity, the percentage ownership of the company held by existing stockholders will be reduced and those stockholders may experience significant dilution. In addition, new securities may contain rights, preferences or privileges that are senior to those of our common stock.

Our independent registered public accounting firm's report to our financial reports for the fiscal year ended June 30, 2009, stated that there was a substantial doubt that we will be able to continue as a going concern. There can be no assurance that acceptable financing to fund our ongoing operations can be obtained on suitable terms, if at all. If we are unable to obtain the financing necessary to support our operations, we may need to take measures to reduce our operating costs, or, if such measures will not be sufficient, we may be unable to continue as a going concern. In that event, we may be forced to cease operations and our stockholders could lose their entire investment in our company.

RESULTS OF OPERATIONS – SIX AND THREE MONTHS ENDED DECEMBER 31, 2009 COMPARED TO SIX AND THREE MONTHS ENDED DECEMBER 31, 2008.

We have not generated any revenues, and we have negative cash flow from operations of \$19,632,000 and have accumulated a deficit of \$36,100,000 since our inception in May 2001. This negative cash flow is mostly attributable to research and development, clinical program and general and administrative expenses. We estimate our net operating cash expenses in the next 12 months will be approximately \$6,000,000.

Research and Development

Research and development expenses, net, for the six months ended December 31, 2009 increased by 39% from \$1,302,000 for the six months ended December 31, 2008 to \$1,814,000. The increase is mainly due to the timing of approval of grants from the OCS. The grant for the period March through December 2008 was approved and recorded only in December 2008. Therefore, in the six months ended December 31, 2008 we recorded an OCS grant in the amount of \$1,329,000, which actually covers OCS support for 10 months of research and development activity. The OCS grant recorded during the six months ended December 31, 2009 amounted to \$989,000, and relates to OCS support for only 6 months of research and development activity. In addition, during the six months ended December 31, 2009 we increased our research and development expenses due to recruitment of new employees to support our clinical trials. Such increase was mainly in payment of salaries and benefits, as well as purchase of materials.

Research and development expenses, net, for the three months ended December 31, 2009 increased from \$39,000 for the three months ended December 31, 2008 to \$947,000. The increase is attributed mainly to timing issues of approval of OCS grants: our expenses in the three months ended December 31, 2009, are reduced by \$500,000 which were approved by the OCS as a grant to support our research and development during that quarter. The OCS grant included in the three months ended December 31, 2008, amounted to \$1,329,000 and relates to OCS support of our research and development activities for a period of 10 months. In addition, during the three months ended December 31, 2009 we increased our research and development expenses due to recruitment of new employees to support our clinical trials activity. Such increase was mainly in payment of salaries and benefits.

General and Administrative

General and administrative expenses for the six months ended December 31, 2009 decreased by 4% from \$1,707,000 for the six months ended December 31, 2008 to \$1,645,000. The decrease is attributable to the decrease in the amount attributed to stock-based compensation to employees and consultants, from \$659,000 to \$501,000, respectively.

General and administrative expenses for the three months ended December 31, 2009 increased by 13% from \$774,000 for the three months ended December 31, 2008 to \$875,000. The increase in general and administrative expenses is primarily attributable to investor and public relations related expenses.

Financial Income, net

Financial income increased from an expense of \$66,000 for the six months ended December 31, 2008 to an income of \$11,000 for the six months ended December 31, 2009. The increase in the financial income is due to a loss from the sale of marketable securities that occurred during the six months ended December 31, 2008.

Financial expenses decreased from an expense of \$20,000 for the three months ended December 31, 2008 to an expense of \$9,000 for the three months ended December 31, 2009 due to exchange rate adjustments.

Net Loss

Net loss for the six and three months ended December 31, 2009 was \$3,448,000 and \$1,831,000, respectively, as compared to net loss of \$3,075,000 and \$833,000 for the six and three months ended December 31, 2008, respectively. Net loss per share for the six and three months ended December 31, 2009 was \$0.22 and \$0.10, respectively, as compared to \$0.35 and \$0.09 for the six and three months ended December 31, 2008. The net loss per share decreased as a result of the increase in our weighted average number of shares following the issuance of additional shares since December 31, 2008.

Liquidity and Capital Resources

As of December 31, 2009, total current assets were \$4,057,000 and total current liabilities were \$1,057,000. On December 31, 2009, we had a working capital surplus of \$3,000,000 and an accumulated deficit of \$36,100,000. We finance our operations and plan to continue doing so with issuances of securities and with funds from grants from the OCS.

Cash and cash equivalents as of December 31, 2009 amounted to \$1,383,000. This is a decrease of \$956,000 from the \$2,339,000 reported as of June 30, 2009. Cash balances decreased in the six months ended December 31, 2009 for the reasons presented below.

Operating activities used cash of \$1,902,000 in the six months ended December 31, 2009. Cash used by operating activities in the six months ended December 31, 2009 primarily consisted of payments of salaries to our employees, and payments of fees to our consultants, subcontractors and professional services providers including costs of the clinical trials, less research and development grants by the OCS.

Investing activities used cash of \$2,631,000 in the six months ended December 31, 2009. The investing activities consisted of investment of \$2,500,000 in a short-term bank deposit and the purchase of equipment for our R&D facilities in the amount of \$124,000.

Financing activities generated cash of \$3,577,000 during the six months ended December 31, 2009 related to the offerings described below.

On July 7, 2009, we announced that the first patient has been enrolled in a Phase I clinical trial of our PLX-PAD product. Upon the occurrence of such event, certain investors had an option to purchase additional shares and warrants (the "Option"). Accordingly, such certain investors purchased, in July 2009, 1,058,708 shares of common stock at a purchase price of \$0.75 per share, for an aggregate purchase price of \$794,000, and warrants to purchase up to an additional 1,058,708 shares of common stock with an exercise price of \$1.50 per share. The warrants are exercisable for a period of 4 years and six months commencing six months following the issuance.

On October 12, 2009, certain institutional investors purchased 2,702,822 shares of our common stock and warrants to purchase 1,081,129 shares of common stock. The price per share of common stock was \$1.12, and the exercise price

of the warrants was \$1.60. The warrants are exercisable for a period of five years commencing six months following the issuance thereof. Roth Capital Partners, LLC acted as placement agent, on a reasonable efforts basis, for the offering. The offering was made pursuant to our shelf registration statement on Form S-3. The gross proceeds we received from this offering were approximately \$3,027,000. Total cash costs related to this placement amounted to \$242,000.

The OCS has supported our activity since 2006. The OCS approved our application for a fourth year's grant in an amount of \$2.3 million for participation in R&D expenses for the period March 2009 to February 2010. Out of such amount we have already received \$1,228,000. We believe that the funds we have, together with the approved R&D grant from the OCS, will be sufficient for operating until at least September 2010.

Our independent registered public accounting firm's report to our financial reports for the fiscal year ended June 30, 2009, states that there is a substantial doubt that we will be able to continue as a going concern. Management believes that we will need to raise additional funds before we have any cash flow from operations. We are looking constantly for sources of funding, including non-diluting sources such as the OCS grants. We have an effective shelf registration statement which we have used in recent public offerings we made and may continue to use in the future to raise additional funds.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

Item 4T. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures - We maintain a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and our Chief Financial Officer ("CFO"), as appropriate to allow timely decisions regarding required disclosures.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and our CFO, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the second quarter of fiscal 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 4. Submission of Matters to the Votes of Security Holders.

Our annual meeting of stockholders was held on December 17, 2009. Of the 18,502,750 shares entitled to vote, stockholders representing 10,922,572 shares were present in person or by proxy.

Zami Aberman, Israel Ben-Yoram, Isaac Braun, Mark Germain, Hava Meretzki, Nachum Rosman, Doron Shorrer and Shai Pines were elected to serve as directors of the company until the next annual meeting of the stockholders or until their successors are elected and qualified or their earlier resignation or removal.

The votes received were as follows (there were no broker non-votes with respect to the election of directors):

	Zami Aberman	Israel Ben-Yoram	Isaac Braun	Mark Germain	Hava Meretzki	Nachum Rosman	Doron Shorrer	Shai Pines
For	10,637,354	10,124,808	10,133,117	8,194,400	10,208,147	10,323,122	10,323,026	10,130,673
Against	210,229	101,371	93,562	2,653,171	212,109	100,227	96,050	95,505
Abstain	74,989	696,393	695,893	75,002	502,318	499,224	503,500	696,393
Not voted	-	-	-	-	-	-	-	-

In addition, our stockholders approved an amendment to the amended Articles of Incorporation of the Company to increase the number of authorized shares of Common Stock from 30,000,000 shares, par value \$0.00001 per share to 100,000,000 shares, par value \$0.00001 per share. Holders of 8,641,651 shares voted “for”, holders of 2,244,903 shares voted “against” and holders of 36,018 shares abstained. There were no broker non-votes with respect to this proposal.

Item 6. Exhibits.

- 3.1* Amended and Restated Articles of Incorporation of the company, as amended as of December 22, 2009.
- 3.2* Amended and Restated Articles of Incorporation of the company, as amended as of December 22, 2009 (marked).
- 4.1 Form of Common Stock Purchase Warrant dated October 12, 2009 issued by the company (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed on October 6, 2009).
- 10.2 Form of Securities Purchase Agreement dated October 6, 2009 (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on October 6, 2009).
- 31.1* Rule 13a-14(a) Certification of Chief Executive Officer.
- 31.2* Rule 13a-14(a) Certification of Chief Financial Officer.
- 32.1** Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
- 32.2** Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

*Filed herewith.

**Furnished herewith.

7

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

By: /s/ Zami Aberman
Zami Aberman, Chief Executive Officer
(Principal Executive Officer)
Date: February 11, 2010

By: /s/ Yaky Yanay
Yaky Yanay, Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
Date: February 11, 2010

8
